Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4552W HIGH $3.65
Volume
8.93 K
Value Traded
934.32 K
Short % Float
8.8%
-4.02%Week
-60.02%1 Month
-71.44%3 Month
-76.48%6 Month
-88.79%5 Year
-88.79%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
90.30 M
EPS (TTM)
-1.13
P/E Ratio
-
Ent. Value
86.23 M
Total Shares
187.90 M
Float Shares
79.28 M
Insiders
57.80%
Institutions
26.92%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NMRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Neumora Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neumora Therapeutics, Inc.
146Total events
10Upcoming
47Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Joshua Pinto appointed CEO and Paul Berns appointed Executive Chair
▲IND Enabling CompleteNMRA-215Preclinical
Favorable 13-week rat toxicology results for NMRA-215
obesity and cardiometabolic diseasesource ↗
▲Preclinical PoCNMRA-215Preclinical
Favorable repeat 13-week rat toxicology study results for NMRA-215
obesity and cardiometabolic diseasesource ↗
▼Primary Endpoint MissedNavacaprantFiledClinical Data
KOASTAL-2 did not achieve statistical significance on primary endpoint
major depressive disordersource ↗
▼Program DiscontinuationNavacaprantFiledCorporate
Company discontinuing development of navacaprant
major depressive disordersource ↗
◆Oral PresentationPresentation
Fireside chat at 2026 RBC Capital Markets Global Healthcare Conference
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
◆Topline ReadoutNavacaprantFiledClinical Data
Joint topline readout for KOASTAL-2 and -3 expected in Q2 2026
major depressive disordersource ↗
◆Timing GuidanceNMRA-861Presentation
Comprehensive franchise update for M4 PAM franchise
schizophrenia and other neuropsychiatric disorderssource ↗
▲Full ResultsNMRA-511Clinical Data
New Phase 1b pre-specified analysis data for NMRA-511 announced
Alzheimer's disease agitationsource ↗
▲Development Candidate NominationNMRA-898Preclinical
NMRA-898 selected as lead M4 franchise program
schizophreniasource ↗
▲Preclinical PoCNMRA-215Preclinical
Positive 12-week DIO study data for NMRA-215 announced
obesitysource ↗
◆Oral PresentationPresentation
Participation in Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat
▲Full ResultsNMRA-511Clinical Data
Full results from Phase 1b study of NMRA-511 presented at Guggenheim Emerging Outlook: Biotech Summit
Alzheimer's disease agitationsource ↗
◆Oral PresentationNMRA-511Presentation
Oral presentation of NMRA-511 Phase 1b data at Guggenheim Emerging Outlook: Biotech Summit
Alzheimer's disease agitationsource ↗
▲Topline ReadoutNMRA-511Clinical Data
Positive topline results from Phase 1b study of NMRA-511 in AD agitation
Alzheimer's disease agitationsource ↗
▲Full ResultsNMRA-511Clinical Data
Positive Phase 1b results for NMRA-511 in AD agitation
Alzheimer's disease agitationsource ↗
▲Enrollment CompleteNavacaprantFiledTrial
KOASTAL-2 fully enrolled in Q1 2026
major depressive disordersource ↗
◆Topline ReadoutNavacaprantFiledClinical Data
Topline data from KOASTAL-3
major depressive disordersource ↗
◆Topline ReadoutNMRA-511Clinical Data
Data from Phase 1b signal-seeking study of NMRA-511
Alzheimer's disease agitationsource ↗
▲Trial InitiationNMRA-898Trial
Initiated second Phase 1 study for M4 PAM franchise (NMRA-898)
schizophrenia and other neuropsychiatric disorderssource ↗
▲Debt Royalty FinancingCorporate
Drew $40 million from venture debt facility with K2 HealthVentures
◆Topline ReadoutNMRA-511Clinical Data
Upcoming Phase 1b topline data readout for NMRA-511
Agitation in Alzheimer's diseasesource ↗
▲Trial InitiationNMRA-898Trial
Initiation of Phase 1 SAD/MAD study of NMRA-898
schizophrenia and other neuropsychiatric disorderssource ↗
▲Preclinical PoCNMRA-215Preclinical
Positive preclinical data for NMRA-215 in diet-induced obesity mouse models demonstrating weight loss
obesitysource ↗
▲Preclinical PoCNMRA-215Preclinical
Class-leading data from DIO mouse model with NMRA-215
obesitysource ↗
▲Trial InitiationNMRA-861Trial
Initiation of Phase 1 SAD/MAD study of NMRA-861
schizophrenia and other neuropsychiatric disorderssource ↗
◆Topline ReadoutNavacaprantFiledClinical Data
Phase 2 data for navacaprant in BPD expected 2H25
Bipolar Depressionsource ↗
◆Topline ReadoutNMRA-511Clinical Data
Phase 1b data for NMRA-511 expected 2H25
Agitation in Alzheimer's Diseasesource ↗
◆Topline ReadoutNavacaprantFiledClinical Data
Topline data from Phase 2 trial of navacaprant in bipolar depression expected in H2 2025
bipolar depressionsource ↗
▲Debt Royalty FinancingCorporate
Secured $125 million venture debt facility from K2 HealthVentures
Past FDA Catalysts and PDUFA Decisions
How NMRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-31 | NMRA-215 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$25M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 51%
Micro Cap(rank 336 of 658)
Percentile Rank
Neumora Therapeutics, Inc. faces pipeline headwinds (36/100), with $915M risk-adjusted pipeline value, led by NMRA-335140 in Major Depressive Disorder (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NMRA-335140 Small moleculeCompletedNCT04221230 | Major Depressive Disorder | Phase 3 | COMPLETED | 1,439 | Jun 23, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every NMRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| navacaprant | major depressive disorder | Phase 3 | 2026-06-15 | KOASTAL 2 enrollment: 430; KOASTAL 3 enrollment: 422; patients analyzed: 426Read More | Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Aurora Daljit SinghOfficer (See Remarks) | Option | 20,553 69,303 held | $0.72 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NMRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.1 % (-50 %) | 3.64 M | 2.14 M | 165.83% ( 1.33 M) |
NMRA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NMRA ranks across every disease it competes in
Competitive Position is a premium feature
See how NMRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNMRA News
NMRA▼ -7.5%on this news
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics reported its Q2 2026 financial results, highlighting progress in its therapeutic pipeline, including NMRA-215, NMRA-511, and NMRA-898. The company plans to submit an IND for NMRA-215 and initiate a Phase 1 study by the end of 2026. Leadership changes include Joshua Pinto as CEO and Paul L. Berns as Executive Chair. Neumora's cash reserves are projected to sustain operations through Q3 2027.
Read more →NMRA▲ +11.4%on this news
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Neumora Therapeutics announced favorable results from a repeat toxicology study of NMRA-215, an oral NLRP3 inhibitor aimed at treating obesity and cardiometabolic diseases. The company plans to submit an IND application in Q4 2026, following the absence of adverse findings in the new study. NMRA-215 shows promise in achieving significant weight loss and improving cardiometabolic risk factors.
Read more →NMRA▼ -48.6%on this news
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies for navacaprant in major depressive disorder failed to meet primary endpoints, leading to the discontinuation of its development. Despite this setback, the company remains optimistic about its other programs, including NMRA-511 for Alzheimer's agitation and NMRA-898 for schizophrenia. Neumora plans to reduce its workforce by 35% to achieve cost savings while maintaining a cash runway into Q3 2027.
Read more →NMRA▼ -6.3%on this news
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
Neumora Therapeutics will participate in the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company aims to redefine neuroscience drug development with its innovative therapeutic pipeline. A live webcast of the event will be available on their website, with a replay accessible for 30 days post-event.
Read more →NMRA▼ -16.7%on this news
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics reported its first quarter 2026 financial results, highlighting significant progress in its clinical trials, including the KOASTAL-2 and -3 studies for navacaprant. The company has a strong cash position of $147.1 million, expected to support operations into Q3 2027. Data from ongoing studies for NMRA-511 and NMRA-898 is anticipated in the second half of 2026.
Read more →NMRA▲ +6%on this news
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
Neumora Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The event will feature a fireside chat at 10:15 a.m. ET, with a live webcast available on their website. Neumora aims to redefine neuroscience drug development with novel therapies.
Read more →NMRA▼ -17.2%on this news
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Neumora Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position and advancements in its clinical pipeline. The company announced promising data for NMRA-511 in Alzheimer's disease agitation and confirmed full enrollment in the KOASTAL-2 and -3 studies. Despite a net loss, Neumora remains on track for significant milestones in 2026.
Read more →NMRANeumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Read more →NMRAFebruary 2026 Guggenheim Emerging Outlook: Biotech Summit Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” &#x
Neumora Therapeutics, Inc. presented forward-looking statements regarding their developments in neuroscience drug development, especially focusing on NMRA-511 for Alzheimer's disease agitation. The data from Phase 1b trials highlighted NMRA-511's superior efficacy compared to its placebo in reducing agitation symptoms, particularly among patients with elevated anxiety. However, there are inherent risks associated with drug development, including reliance on third parties and potential side effects that need further assessment.
Read more →NMRANeumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Neumora Therapeutics, a clinical-stage biopharmaceutical company, will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The event will feature a fireside chat, which will be available via live webcast on the company's website. Neumora aims to redefine neuroscience drug development with its innovative therapeutic pipeline.
Read more →NMRAImportant Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including statements r
Neumora Therapeutics is focused on advancing neuroscience by developing novel therapies aimed at improving treatment outcomes for various neurological conditions. The company is preparing for key clinical trials and anticipates several significant milestones in 2026, while maintaining a strong financial position. However, inherent risks in clinical development and reliance on external partners remain. Future results are uncertain and contingent on several factors outlined in their disclosures.
Read more →NMRANeumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
Neumora Therapeutics announced its 2026 pipeline strategy, highlighting several key clinical milestones, including the joint readout of KOASTAL-2 and KOASTAL-3 and the initiation of the NMRA-215 program. The company reported positive Phase 1b results for NMRA-511, indicating a meaningful effect on Alzheimer's agitation. Neumora is well-positioned financially to support its operations through 2027.
Read more →NMRANeumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
Neumora Therapeutics announced positive results from its Phase 1b study of NMRA-511 for Alzheimer's disease agitation. The study demonstrated a significant reduction in agitation symptoms and a favorable safety profile. Neumora plans to advance NMRA-511's development, including exploring higher doses in future cohorts.
Read more →NMRANeumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Neumora Therapeutics reported strong third quarter results, highlighting class-leading data from NMRA-215, an oral NLRP3 inhibitor, and plans to initiate a Phase 1 study in early 2026. The company is also advancing Phase 1 studies for two positive allosteric modulators and expects to report data from a Phase 1b study in Alzheimer's agitation by year-end. Neumora's financial position remains robust with $171.5 million in cash, supporting operations into 2027.
Read more →NMRANeumora Therapeutics to Participate in Upcoming Conferences in November
Neumora Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences scheduled for November. The company aims to showcase its innovative pipeline, which includes seven programs targeting novel mechanisms for treating prevalent diseases. Live webcasts of the events will be accessible on their website, with replays available for 30 days.
Read more →NMRANeumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Neumora Therapeutics has initiated a Phase 1 clinical study for NMRA-898, a positive allosteric modulator targeting the M4 muscarinic receptor. This follows the earlier initiation of a similar study for NMRA-861. Both compounds aim to improve treatment options for schizophrenia, potentially offering better safety profiles than existing therapies. A comprehensive update on the M4 franchise is expected by mid-2026.
Read more →NMRANeumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Neumora Therapeutics announced promising preclinical results for NMRA-215, a novel oral NLRP3 inhibitor, showing up to 26% weight loss in combination with semaglutide. The drug demonstrated significant efficacy as a monotherapy as well. Neumora plans to begin Phase 1 clinical studies in the first quarter of 2026, reinforcing its commitment to innovative obesity treatments.
Read more →NMRANeumora Therapeutics to Host Virtual R&D Day on October 27
Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, to present its innovative pipeline. The event will highlight NMRA-215, a potent NLRP3 inhibitor, and discuss expectations for NMRA-511's Phase 1b data. Neumora aims to redefine neuroscience drug development with its seven programs targeting significant medical challenges.
Read more →NMRANeumora Therapeutics to Participate in Upcoming Conferences in September
Neumora Therapeutics to Participate in Upcoming Conferences in September
Read more →NMRANeumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Neumora Therapeutics has reported its financial results for Q2 2025, highlighting its active pipeline and business updates. The company initiated a Phase 1 study for NMRA-861, a positive allosteric modulator with potential in schizophrenia, with data expected in early 2026. Additionally, NMRA-215 has been prioritized as the lead indication for obesity, aiming to address unmet needs in weight loss therapies. Neumora also anticipates several critical clinical data readouts over the next year and maintains a strong cash position of $217.6 million.
Read more →About Neumora Therapeutics, Inc.
Headquarters260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
BIOPHARMAWATCH ELITE PLUS
Trade the next NMRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime